CMPX (Compass Therapeutics) Ending Cash Position: $55.74 Mil (As of Mar. 2026)


CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics Ending Cash Position?

Compass Therapeutics CMPX +0.86% 23 Ending Cash Position is $55.74 Mil as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Compass Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $55.74 Mil.

Compass Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($46.78 Mil) to Dec. 2025 ($31.21 Mil) but then increased from Dec. 2025 ($31.21 Mil) to Mar. 2026 ($55.74 Mil).

Compass Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($24.23 Mil) to Dec. 2024 ($43.48 Mil) but then declined from Dec. 2024 ($43.48 Mil) to Dec. 2025 ($31.21 Mil).

Compass Therapeutics Ending Cash Position Related Terms

Compass Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Ending Cash Position Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 144.51 34.95 24.23 43.48 31.21

Compass Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.62 23.42 46.78 31.21 55.74
CMPX
23GF Score
Compass Therapeutics Inc CMPX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Compass Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=44.051+-12.84
=31.21

Compass Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=31.211+24.525
=55.74

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $55.74 Mil mean?
Compass Therapeutics (CMPX) has a Ending Cash Position of $55.74 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Compass Therapeutics and its competitors.
Is Compass Therapeutics' Ending Cash Position too high?
Compass Therapeutics' current Ending Cash Position is $55.74 Mil. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Ending Cash Position compare to XFOR and LRMR?
Compass Therapeutics' Ending Cash Position of $55.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current Ending Cash Position is $55.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Ending Cash Position of $55.74 Mil. The current Ending Cash Position is $55.74 Mil. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Ending Cash Position is $55.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price